CPI-360 is a potent and selective small molecule inhibitor of EZH2, demonstrating sub-nanomolar enzymatic inhibition and cellular activity. It has shown antitumor efficacy in EZH2-dependent xenograft models, supporting its use as a chemical probe for epigenetic research in oncology, both in vitro and in vivo.